Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 26, 24 | -0.36 Increased by +25% | -0.44 Increased by +18.18% |
| Nov 13, 23 | -0.43 Increased by +15.69% | -0.5 Increased by +14% |
| Aug 7, 23 | -0.47 Increased by +51.04% | -0.54 Increased by +12.96% |
| May 8, 23 | -0.52 Increased by +43.48% | -0.52 |
| Mar 6, 23 | -0.48 Increased by +50.52% | -0.53 Increased by +9.43% |
| Nov 3, 22 | -0.51 Increased by +45.16% | -0.86 Increased by +40.7% |
| Aug 8, 22 | -0.96 Decreased by -17.07% | -0.94 Decreased by -2.13% |
| May 9, 22 | -0.92 Decreased by -35.29% | -1 Increased by +8% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -32.48 M Increased by +4.57% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -35.19 M Increased by +4.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -35.57 M Decreased by -0.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -32.07 M Increased by +14.18% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -34.04 M Increased by +4.38% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -36.87 M Decreased by -17.8% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -35.32 M Decreased by -35.81% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -37.37 M Decreased by -61.13% | Decreased by N/A% Decreased by N/A% |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.